According to a new research study by Global Insight Services (GIS), the allergy diagnostics market is expected to grow rapidly over the next 10 years to reach a value of more than the US $5billion by 2031.
An allergy is a hypersensitivity condition of the immune system. Allergic reactions occur when a person’s immune system reacts to harmless substances which are named allergens in the environment. Major allergens that affect the immune system are dust mites’ excretion, pollen, and pet dander. There are different kinds of allergies such as food allergy, skin allergy, dust allergy, allergy to insect stings, drug allergy, and mold allergy. Food allergy is generally caused by the consumption of certain proteins found in food and may activate symptoms such as hives and digestive problems.
Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10236/
Allergy Diagnostics Market: Key Drivers
Increasing environmental pollution levels
Exposure to indoor and outdoor air pollutants, allergens, and occupational exposure are the major risk factors that cause chronic respiratory diseases. The prevalence of allergic disorders among the urban population is higher than those living in rural areas owing to the high exposure to environmental pollutants in cities. A new WHO air quality model confirms that 92% of the world’s population lives in places where air quality levels exceed WHO limits. Some 3 million deaths per year are linked to exposure to outdoor air pollution. Indoor air pollution can be just as deadly. In 2012, an estimated 6.5 million deaths (11.6% of global deaths) were associated with indoor and outdoor air pollution together.
Use of mHealth in allergy diagnosis
Recent developments in integrated biosensors, wireless communication, and power harvesting techniques generate a new class of point-of-care devices. Conversely, AR is a very common disease. Any diagnostic device connected to a smartphone (e.g., peak nasal inspiratory flow meters or intranasal biosensors) would need to be inexpensive to be affordable.
The monitoring of the control of allergic multimorbidity (rhinitis, conjunctivitis, and asthma) has been approached by various apps. An allergy monitor, for instance, assists in monitoring the symptoms and medication intake, which is then matched to local pollen concentrations.
The consumable segment is likely to dominate the market at a constant rate of XX% during the forecast period.
The key factors such as rising cases of allergies coupled with the need for rapid tests to diagnose allergic conditions are likely to boost the growth of the segment during the forecast period.
The inhaled allergens segment is estimated to dominate the market at a CAGR of XX% during the forecast period.
The key factors such as increasing environmental pollution combined with rising pollen coupled with other factors like fungus, mold, and dust are propelling the growth of the segment in the market.
In vivo tests is likely to dominate the global allergy diagnostics market at a constant rate of XX% during the forecast period.
The key factors such as increasing adoption of various in vivo tests, such as skin prick test is boosting the growth of the segment. These tests are dependable, safe, convenient, and cost-effective, as compared to in vitro tests.
The diagnostic laboratories segment is likely to dominate the market at a CAGR of XX% during the forecast period.
The large share of the segment can be primarily attributed to the preference for proper diagnosis from a specialist coupled with rising awareness regarding the management of allergic diseases, and the availability of funds for the operation of independent diagnostic laboratories. These factors are likely to propel the growth of the segment during the forecast period.
The key players in the global allergy diagnostics market are Thermo Fisher Scientific Inc., Siemens Healthineers, Danaher, Omega Diagnostics Group PLC, bioMérieux SA, Romer Labs Division Holding, EUROIMMUN Medizinische Labordiagnostika AG, HollisterStier Allergy, NEOGEN Corporation, Eurofins Scientific, Minaris Medical America, Inc., Stallergenes Greer, HOB Biotech Group Corp., Ltd., HYCOR Biomedical, R-Biopharm AG, AESKU.GROUP GmbH, ACON Laboratories, Inc., Lincoln Diagnostics, Inc., Astra Biotech GmbH, and Erba Group among others.